4 Analysts Assess Arrowhead Pharma: What You Need To Know
Portfolio Pulse from Benzinga Insights
Arrowhead Pharma (NASDAQ:ARWR) has been analyzed by 4 analysts, showing a mix of bullish and indifferent sentiments. The average 12-month price target is $38.25, up from the previous $34.50. Analysts from B of A Securities and Morgan Stanley have adjusted their price targets, while RBC Capital maintains a high estimate. Arrowhead's financials indicate a market cap above industry average, a significant revenue decline, high net margin, and low ROE and ROA. The company has a conservative debt-to-equity ratio.
January 02, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Arrowhead Pharma's average 12-month price target has been raised to $38.25, indicating a bullish sentiment among analysts. The company's financials show a strong market cap but a decline in revenue and challenges in profitability and asset utilization.
The increase in the average price target suggests a positive outlook for ARWR, which could lead to a short-term price increase. However, the decline in revenue and low profitability metrics may temper investor enthusiasm, potentially limiting the upside.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100